Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain

Circulation

Volumn 96, Issue 5, 1997, Pages 1501-1506

  Matsumori, Akira ^a   Ono, Koh ^a   Nishio, Ryosuke ^a   Igata, Hideki ^a   Shioi, Tetsuo ^a   Matsui, Shigeo ^a   Furukawa, Yutaka ^a   Iwasaki, Atsushi ^a   Nose, Yoshisuke ^b   Sasayama, Shigetake ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

Heart failure; Inotropic agents; Interleukins; Shock; Tumor necrosis factor

Indexed keywords

AMILORIDE; CARDIAC GLYCOSIDE; CYTOKINE; DACTINOMYCIN; GENISTEIN; INOTROPIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; OUABAIN; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; ENDOTOXEMIA; HEART FAILURE; HUMAN; HUMAN CELL; IMMUNOREGULATION; MONONUCLEAR CELL; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0343554056     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.5.1501     Document Type: Article

References (36)

1. Withering W. An account of the foxglove and some of its medical uses, with practical remarks on dropsy, and other diseases. In: Willis FA, Keys TE, eds. Classics of Cardiology. Vol 1. New York, NY: Henry Schuman, Dover Publications; 1941:231-252.
2. Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ, Smith LK, Van-Voorhees L, Gourley LA, Jolly MK, for the RADIANCE Study Group. Withdrawal of digoxin in patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitor. N Engl J Med. 1993;329:1-7.
3. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, on behalf of the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED Trial. J Am Coll Cardiol. 1993;22:955-962.
4. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
5. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: suppression of natural killer cell activity and tumor necrosis factor-α production. J Clin Invest. 1994; 94:1212-1217.
6. Shioi T, Matsumori S, Matsui S, Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci. 1994;54: PL11-PL16.
7. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994;89:955-958.
8. Matsumori A, Ono K, Sato Y, Shioi T, Nose Y, Sasayama S. Differential modulation of cytokine production by drugs: implications for therapy in heart failure. J Mol Cell Cardiol. 1996;28: 2491-2499.
9. Lingrel JB, Kuntzweiler T. Na+, K(+)-ATPase. J Biol Chem. 1994; 269:19659-19662.
10. Schwartz A, Lindenmayer GE, Allen JC. The sodium-potassium adenosine triphosphatase: pharmacological, physiological and biochemical aspects. Pharmacol Rev. 1975;27:3-134.
11. Schwartz A. Is the cell membrane Na+, K+-ATPase enzyme system the pharmacological receptor for digitalis? Circ Res. 1976; 39:2-7.
12. Akera T. Membrane adenosinetriphosphatase: a digitalis receptor? Science. 1977;198:569-574.
13. Yamato K, El-Hajjaoui Z, Kuo JF, Koeffler HP. Granulocyte-macrophage colony-stimulating factor: signals for its mRNA accumulation. Blood. 1989;74:1314-1320.
14. Akashi M, Loussararian AH, Adelman DC, Saito M, Koeffler HP. Role of lymphotoxin in expression of interleukin 6 in human fibroblasts: stimulation and regulation. J Clin Invest. 1990;85:121-129.
15. Nakagawa Y, Rivera V, Larner AC. A role for the Na/K-ATPase in the control of human c-fos and c-jun transcription. J Biol Chem. 1992;267:8785-8788.
16. Peng M, Huang L, Xie Z, Huang W-H, Askari A. Partial inhibition of Na+/K+-ATPase by ouabain induces the Ca2+-dependent expressions of early-response genes in cardiac myocytes. J Biol Chem. 1996;271:10372-10378.
17. Otani H, Otani H, Morita M, Das DK. Effect of calcium overload on the phosphoinositide breakdown in the rat left ventricular papillary muscle. Mol Cell Biochem. 1989;90:111-120.
18. Gotoh H, Kamiyama A, Shibayama R, Sawada M, Kashimoto T. Involvement of phosphoinositide turnover in ouabain inotropism. Biochem Biophys Res Commun. 1993;194:72-78.
19. Prpic V, Weiel JE, Somers SD, DiGuiseppi J, Gonias SL, Pizzo SV, Hamilton TA, Herman B, Adams DO. Effects of bacterial lipopolysaccharide on the hydrolysis of phosphatidylinositol-4, 5-Bisphosphate in murine peritoneal macrophages. J Immunol. 1987;139:526-533.
20. Weiel JE, Hamilton TA, Adams DO. LPS induces altered phosphate labeling of proteins in murine peritoneal macrophages. J Immunol. 1986;136:3012-3018.
21. Nelson DJ, Jow B, Jow F. Lipopolysaccharide induction of outward potassium current expression in human monocyte-derived macrophages: lack of correlation with secretion. J Membrane Biol. 1992; 125:207-218.
22. Chordera A, Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm. 1978;16:357-360.
23. Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest. 1994;105: 897-904.
24. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
25. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.
26. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-389.
27. Hocking DC, Phillips PG, Ferro TJ, Johnson A. Mechanisms of pulmonary edema induced by tumor necrosis factor-α. Circ Res. 1990;67:68-77.
28. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet. 1990;335:294-295. Letter.
29. Hosenpud JD, Campbell SM, Mendelson DJ. Interleukin-1-induced myocardial depression in an isolated beating heart preparation. J Heart Transplant. 1989;8:460-464.
30. Evans HG, Lewis MJ, Shah AM. Interleukin-1β modulates myocardial contraction via dexamethasone-sensitive production of nitric oxide. Cardiovasc Res. 1993;27:1486-1490.
31. Weisensee D, Bereiter-Hahn J, Schoeppe W, Low-Friedrich I. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol. 1993;15:581-587.
32. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β. J Clin Invest. 1995;95:677-685.
33. Woodley SL, McMillan M, Shelby J, Lynch DH, Roberts LK, Ensley RD, Barry WH. Myocyte injury and contraction abnormalities produced by cytotoxic T lymphocytes. Circulation. 1991;83: 1410-1418.
34. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 1995;96:1093-1099.
35. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995;92:4862-4866.
36. Katz AM. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med. 1994;121: 363-371.